HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period
HALOZYME THERAPEUTICS, INC. (HALO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period of 6.50 million shares for the 9-month period ending 2012-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod · last filed 2013-11-08
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2012-09-30 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 9 month |
|---|---|---|---|
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | 6.50M shares 10-Q · filed 2013-11-08 | |
| 2012-06-30 | 6.50M shares 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |